ELDN.NASDAQEledon Pharmaceuticals, INC

Form 4: Eledon Pharmaceuticals Executive Acquires 241,650 Shares Through Stock Option Vesting

Sentiment:

SEC Form 4 Filing

📋All filings for Eledon Pharmaceuticals, INC
🔒Login to Follow

Bryan E. Smith, General Counsel and Corporate Secretary of Eledon Pharmaceuticals, acquired 241,650 shares of common stock through the vesting of a stock option on June 13, 2024.

Summary

  • Bryan E. Smith, General Counsel and Corporate Secretary of Eledon Pharmaceuticals, filed a Form 4 on June 14, 2024, reporting a change in beneficial ownership.
  • On June 13, 2024, Smith acquired 241,650 shares of Eledon Pharmaceuticals common stock through the vesting of a stock option.
  • The stock option, granted on May 1, 2023, had a strike price of $2.30.
  • The vesting was contingent on both performance-based and time-based criteria.
  • The performance-based vesting criteria were met for 241,650 shares on June 13, 2024.
  • Time-based vesting criteria were met for 60,413 shares on May 1, 2024.
  • The remaining 181,237 shares will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.
  • Following the transaction, Smith directly owns 241,650 shares of Eledon Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of options suggests the executive is incentivized and that performance targets are being met, but it's a routine transaction.

Positives

  • The vesting of stock options indicates that performance targets were met, which could be a positive signal for the company's performance.

Future Outlook

The remaining 181,237 shares of the stock option will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders trade their company's stock. This filing indicates the acquisition of shares by an executive, which can be interpreted in various ways depending on the context of the company's performance and outlook.

Stakeholder Impact

  • The acquisition of shares by a company executive could have a slightly positive impact on shareholder confidence.

Key Dates

DateDescription
May 1, 2023Date the stock option was granted to Bryan Smith.
May 1, 2024Time-based vesting criteria met for 60,413 shares.
June 13, 2024Performance-based vesting criteria met for 241,650 shares.
June 14, 2024Date the Form 4 was filed.
May 1, 2027End date for the quarterly vesting of the remaining 181,237 shares.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.